Rethinking CKD Diagnosis in Cats: Why Early Detection Must Go Beyond Creatinine

Chronic kidney disease in cats is one of the most frequently diagnosed chronic conditions in geriatric feline medicine, with an overall prevalence estimated between 2% and 4%, rising dramatically to nearly 30% to 40% in cats older than 10 years of age¹. Similar age-related increases have also been observed in dogs based on large population studies². Despite this high burden, CKD is still most often diagnosed late in its course, when irreversible nephron loss has already occurred and clinical intervention becomes limited to slowing progression rather than preventing disease onset. 

From a clinical standpoint, this delayed diagnosis is not due to lack of awareness but rather reliance on late functional biomarkers and non-specific clinical indicators. In most cats, CKD is diagnosed using a combination of azotemia, compatible clinical signs, and inappropriate urine specific gravity (USG)¹. However, this traditional approach has significant limitations because early renal damage can exist even when these parameters remain within near-normal ranges. 

Limitations of Conventional Diagnostic Markers 

One of the key challenges in feline CKD diagnosis is the interpretation of urine concentrating ability. A USG below 1.035 is generally considered abnormal in dehydrated or azotemic cats, but this threshold is not absolute. Some cats with early CKD may still maintain relatively normal concentrating ability. Conversely, dilute urine is not specific to renal disease and can result from medications such as diuretics, liver disease, glucosuria, or electrolyte imbalances¹. This overlap reduces diagnostic certainty in early disease. 

Histopathologically, CKD in cats is most commonly associated with tubulointerstitial inflammation, often progressing to fibrosis, which is strongly linked to poor prognosis¹. Importantly, these structural changes precede detectable functional decline, creating a diagnostic gap between injury and measurable dysfunction. 

GFR Measurement: The Ideal but Impractical Standard 

Glomerular filtration rate remains the gold standard for evaluating renal function because it directly reflects nephron performance. It can be measured using endogenous or exogenous filtration markers. However, despite advances in limited sampling techniques, GFR measurement remains largely confined to research settings and is not feasible in routine clinical practice¹. This limitation has forced clinicians to depend on indirect serum biomarkers. 

Serum Creatinine: Useful but Fundamentally Insensitive 

Serum creatinine is widely used in practice due to its availability and low cost. It is also relatively stable within individuals¹. However, its clinical limitations are significant. Creatinine is heavily influenced by muscle mass, making it unreliable in cachectic or geriatric cats^1,3. More importantly, it lacks sensitivity for early CKD and cannot detect structural renal injury that does not yet affect filtration capacity. Additionally, its wide biological variability can lead to misclassification of disease stage¹. 

These limitations highlight why creatinine alone is insufficient for early detection. 

SDMA: A More Sensitive Functional Marker 

Symmetric dimethylarginine has emerged as a more sensitive marker of decreased GFR, increasing when renal filtration declines by approximately 40%^1,4. Unlike creatinine, SDMA is not significantly affected by muscle mass, making it particularly useful in geriatric populations. It is now incorporated into IRIS staging guidelines as a marker for early CKD detection^1,5,6. 

However, SDMA still has limitations. Its specificity is not fully established, and it requires repeated measurements for accurate interpretation due to biological variability¹. Despite this, it represents a meaningful improvement over creatinine-based diagnosis. 

Cystatin C: A Biomarker That Did Not Fulfill Expectations 

Serum cystatin C has shown promise in other species as a GFR marker, but in cats its clinical utility is limited. Although freely filtered and metabolized in the proximal tubules, assay cross-reactivity issues significantly affect measurement reliability. Additionally, it shows poor sensitivity and cannot reliably distinguish CKD stages or predict disease progression¹. Despite strong theoretical rationale, it has not translated into clinical utility in feline medicine. 

Clinical Implications for Practitioners 

The current diagnostic framework for feline CKD remains heavily dependent on functional decline rather than early injury detection. This creates a significant delay in diagnosis, often missing the window where intervention could meaningfully alter disease trajectory. 

For clinicians, the key takeaway is that CKD should not be viewed solely as a decline in filtration but as a progressive process of silent injury. Early detection requires moving beyond creatinine and incorporating more sensitive biomarkers such as SDMA, alongside a broader understanding of subclinical renal injury. 

References 

1. Kongtasai T, Paepe D, Meyer E, Mortier F, Marynissen S, Stammeleer L, Defauw P, Daminet S. Renal biomarkers in cats: A review of the current status in chronic kidney disease. Journal of veterinary internal medicine. 2022 Mar;36(2):379-96. https://academic.oup.com/jvim/article-pdf/36/2/379/66666729/jvim16377.pdf 

2. Hall JA, Fritsch DA, Yerramilli M, Obare E, Yerramilli M, Jewell DE. A longitudinal study on the acceptance and effects of a therapeutic renal food in pet dogs with IRIS‐stage 1 chronic kidney disease. Journal of animal physiology and animal nutrition. 2018 Feb;102(1):297-307. https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jpn.12692 

3. Reynolds BS, Brosse C, Jeunesse E, Concordet D, Lefebvre HP. Routine plasma biochemistry analytes in clinically healthy cats: within-day variations and effects of a standard meal. Journal of feline medicine and surgery. 2015 Jun;17(6):468-75. https://journals.sagepub.com/doi/pdf/10.1177/1098612X14546920 

4. Hall JA, MacLeay J, Yerramilli M, Obare E, Yerramilli M, Schiefelbein H, Paetau-Robinson I, Jewell DE. Positive impact of nutritional interventions on serum symmetric dimethylarginine and creatinine concentrations in client-owned geriatric dogs. PLoS One. 2016 Apr 18;11(4):e0153653. https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0153653&type=printable 

5. Paltrinieri S, Giraldi M, Prolo A, Scarpa P, Piseddu E, Beccati M, Graziani B, Bo S. Serum symmetric dimethylarginine and creatinine in Birman cats compared with cats of other breeds. Journal of feline medicine and surgery. 2018 Oct;20(10):905-12.  https://journals.sagepub.com/doi/pdf/10.1177/1098612X17734066 
6. Langhorn R, Kieler IN, Koch J, Christiansen LB, Jessen LR. Symmetric dimethylarginine in cats with hypertrophic cardiomyopathy and diabetes mellitus. Journal of Veterinary Internal Medicine. 2018 Jan;32(1):57-63. https://academic.oup.com/jvim/article-pdf/32/1/57/66672488/jvim14902.pdf